Fitzpatrick steps down as CancerLinQ CEO; ASCO CMO Schilsky named interim CEO

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Kevin Fitzpatrick will step down from his role as CEO of CancerLinQ LLC, a wholly owned non-profit subsidiarity of the American Society of Clinical Oncology, on April 13 to pursue a new opportunity outside of ASCO.

Richard Schilsky, ASCO chief medical officer, will serve as interim CEO. CancerLinQ LLC will initiate a global search for a permanent CEO to oversee the continued expansion and implementation of CancerLinQ.

“Under Kevin’s leadership we’ve taken CancerLinQ from a bold and ambitious idea to a reality for physicians and researchers across the country who seek to learn from everyday patient care,” Clifford Hudis, CEO of ASCO and chair of the CancerLinQ board of governors, said in a statement. “He played a crucial role in establishing CancerLinQ, overseeing its rollout to physician practices and securing novel strategic collaborations with government, for-profit and non-profit entities.

“We are fortunate to have Dr. Schilsky, with his extensive experience with CancerLinQ and oncology data, and his relationships throughout the oncology community, to step in to sustain our momentum through the transition,” Hudis said.

Schilsky is a past president of ASCO and has served as CMO since 2012. In addition to being closely involved with CancerLinQ since its inception. He leads ASCO’s Center for Research & Analytics, which makes various cancer data sets—including CancerLinQ Discovery—available to the oncology community and provides consultation and support for research and analysis.

Last year, ASCO and two companies—Tempus and Precision Health AI—announced a deal to curate and license the data in CancerLinQ. The ten-year collaboration, announced Dec. 21, 1017, gives Tempus and PH.AI access to de-identified data from over a growing database of more than a million records contained in CancerLinQ (The Cancer Letter, Jan. 5)

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login